>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Y-27632

Y-27632 是口服有效的，ATP 竞争性的 ROCK-I 和 ROCK-II 抑制剂，Ki 分别为 220 nM 和 300 nM。Y-27632 减弱阿霉素诱导的人心脏干细胞凋亡 (apoptosis)。Y-27632 还抑制分离诱导的小鼠前列腺干/祖细胞凋亡。Y-27632 通过上皮-间充质过渡样调节引发人诱导多能干细胞 (hIPSCs) 选择性地分化为间胚层谱系。

货号：
TK0261
规格：

1mg

2mg

5mg

10mg
价格：
￥0.00

产品参数

CAS No.	146986-50-7
生物活性	Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation.
分子式	C14H21N3O
分子量	247.34
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	-20°C, protect from light, stored under nitrogen
溶解性数据	DMSO : 50 mg/mL (202.15 mM; Need ultrasonic) H2O : 5 mg/mL (20.22 mM; ultrasonic and warming and heat to 60°C)
体内研究	Y-27632 (5 and 10 mg/kg) significantly prolongs the onset time of myoclonic jerks when compare with saline group. Y-27632 (5 and 10 mg/kg) significantly prolongs the onset time of clonic convulsions when compare with saline group. Treatment with Dimethylnitrosamine (DMN) causes a significant decrease in rat body and liver weight (DMN-S group) compared with control animals (S-S group). Oral Y27632 (30 mg/kg) essentially prevents this DMN-induced rat body and liver weight loss (DMN-Y group).
体外研究	Y-27632 inhibits the ROCK family of kinases 100 times more potently than other kinases including protein kinase C, cAMP-dependent kinase and myosin light chain kinase. Y-27632 prolongs the lag time and delays the appearance of BrdU-labeled cells in a concentration-dependent manner, delays of about 1 and 4 h are noticed in the Swiss 3T3 cells treated with 10 and 100 μM Y-27632, respectively. Y-27632 promotes neuronal differentiation of adipose tissue-derived stem cells (ADSCs). Compared to 1.0 and 2.5 μM Y-27632 induced groups, percentages of neuroal-like cells achieved a peak in the 5.0 μM Y-27632 induced group. Extracellular matrix (ECM) molecules decreases apoptosis markers and inhibiting the ROCK pathway blocks ECM stimulated actin cortical mat reformation and increases apoptosis in embryonic corneal epithelial cells.
文献	•Nature. 2021 Dec 2. •Science. 2020 Dec 4;370(6521):eaay2002. •Cell Stem Cell. 2020 Oct 1;27(4):646-662.e7. •Cell Stem Cell. 2020 Jul 2;27(1):125-136.e7. •Cell Stem Cell. 2020 Jun 4;26(6):845-861.e12. •Mol Cell. 2021 Jul 1;81(13):2736-2751.e8. •Circ Res. 2020 Oct 9;127(9):1182-1194. •Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. •Protein Cell. 2021 Feb;12(2):107-127. •Bioact Mater. 2021 Jun 1. •Sci Adv. 2021 Sep 17;7(38):eabb5933. •Bone Res. 2022 Jan 3;10(1):1. •Nat Protoc. 2021 Jan;16(1):352-382. •Small. 2021 Nov 2;e2104773. •Small. 2021 Jun 8;e2100546. •Biomaterials. 2021, 120684. •Biomaterials. 2020 Nov;258:120284. •Biomaterials. 2020 May;240:119849. •J Exp Clin Cancer Res. 2018 Jun 28;37(1):128. •Cell Discov. 2021 Apr 19;7(1):25. •J Hazard Mater. 2021 Apr 5;407:124387. •J Hazard Mater. 2021 Jan 5;401:123341. •J Hazard Mater. 2020 Jul 5;393:122440. •Adv Healthc Mater. 2021 Feb 15;e2002103. •Cell Rep. 2019 Jan 8;26(2):407-414.e5. •Exp Mol Med. 2021 Sep 21. •Cancer Lett. 2019 Apr 28;448:117-127. •Environ Pollut. 2020 Jun;261:114153. •Sci Total Environ. 2020 Jul 10;725:138433. •Neurotherapeutics. 2021 Jan 21. •J Med Chem. 2019 Jul 11;62(13):6083-6101. •Anal Chem. 2017 Oct 17;89(20):10841-10849. •Stem Cell Res Ther. 2019 May 31;10(1):155. •Front Cell Dev Biol. 2021 Jun 24;9:670825. •Cancers (Basel). 2021, 13(13), 3282. •Breast Cancer Res. 2021 Aug 3;23(1):82. •J Neurosci. 2021 Jan 20;41(3):392-407. •Food Chem Toxicol. 2020 Jan;135:111015. •Mat Sci Eng C-Mater. 2021, 111939. •iScience. 19 October 2021, 103303. •J Cell Mol Med. 2020 Jul;24(14):8179-8193. •Chem Biol Interact. 17 August 2021, 109625. •J Virol. 2021 Feb 24;95(10):e02436-20. •Life Sci. 2020 Apr 1;246:117419. •Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):1. •Front Med. 2021 Sep 23;8:746298. •Front Physiol. 2020 Jun 30;11:669. •Sci Rep. 2021 Dec 7;11(1):23564. •Sci Rep. 2019 Dec 17;9(1):19301. •Sci Rep. 2017 Dec 19;7(1):17770. •Toxicology. 2020 Oct;443:152573. •Nutr Metab. 2020 Oct 26;17:91. •J Bone Oncol. October 2021, 100391. •Oncol Rep. 2020 Sep;44(3):1266-1274. •Biochem Biophys Res Commun. 2021 Mar 18;552:142-149. •Biochem Biophys Res Commun. 2019 Oct 29;519(1):134-140. •Biochem Biophys Res Commun. 2019 Aug 20;516(2):571-577. •Connect Tissue Res. 2022 Jan 12;1-10. •Biomed Res Int. 2021 May 15. •J Clin Med. 2019 Oct 21;8(10):1751. •Brain Res. 15 December 2021, 147684. •Med Sci Monit. 2018 May 27;24:3514-3523. •Exp Ther Med. 2021 Feb 3. •J Biosci Bioeng. 2020 Dec 23;S1389-1723(20)30432-1. •Biosci Biotechnol Biochem. 2021 Jul 23;zbab136. •Stem Cell Res. October 2021, 102544. •Stem Cell Res. 2021, 102217. •Stem Cell Res. 2021, 102157. •BMC Urol. 2021 Jan 6;21(1):5. •Research Square Preprint. 2022 Jan. •STAR Protoc. 2021 Nov 5;2(4):100881. •Research Square Preprint. 2021 Oct. •Patent. US20210284970A1. •Life. 2021, 11(8), 789. •Research Square Preprint. 2021 May. •Research Square Preprint. 2021 Jan. •Bioengineering (Basel). 2020 Dec 18;7(4):164. •Cell Regen. 2020 Sep 3;9(1):15. •cell analysis. 2020 Aug. •bioRxiv. 2020 Aug. •Research Square Preprint. 2020 Aug 20;rs.3.rs-62758. •bioRxiv. 2020 Mar. •Curr Protoc Cell Biol. 2018 Dec;81(1):e62. •Patent. US20180263995A1. •Oncotarget. 2017 Jul 31;8(47):82506-82530. •Harvard Medical School LINCS LIBRARY
纯度及产品资料	98%

推荐产品